{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:33:50Z","timestamp":1773275630828,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine whether patients with carcinoma invading bladder muscle (MIBC) and ureteric obstruction can safely receive cisplatin\u2010based neoadjuvant chemotherapy (C\u2010NAC), and to determine whether such patients require relief of obstruction with a ureteric stent or percutaneous nephrostomy prior to beginning C\u2010NAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We performed a single\u2010institution retrospective analysis of MIBC patients receiving C\u2010NAC and falling into three groups: no ureteric obstruction (NO); relieved ureteric obstruction (RO); and unrelieved ureteric obstruction (URO). To address whether patients with obstruction can safely receive C\u2010NAC, we compared patients with NO to those with RO, with the primary outcome of premature chemotherapy discontinuation. To investigate whether patients with obstruction should have the obstruction relieved prior to NAC, we compared RO to URO patients using a primary composite outcome of grade \u2265 3 adverse events, premature chemotherapy discontinuation, dose reduction, or dose interruption. The primary outcomes were compared using multivariable logistic regression. Sensitivity analyses were performed for the RO vs URO comparison, in which patients with only mild degrees of obstruction were excluded from the URO group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 193 patients with NO, 49 with RO, and 35 with URO were analysed. There were no statistically significant differences between those with NO and those with RO in chemotherapy discontinuation (15% vs 22%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.3) or any secondary outcome. There was no statistically significant difference between those with RO and URO in the primary composite outcome (51% vs 53%;\n                      <jats:italic>P<\/jats:italic>\n                      = 1) or any secondary outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with ureteric obstruction can safely receive C\u2010NAC. Relief of obstruction was not associated with increased safety of C\u2010NAC delivery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.15410","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T08:28:02Z","timestamp":1617006482000},"page":"364-372","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of neoadjuvant chemotherapy in patients with muscle\u2010invasive bladder cancer and malignant ureteric obstruction"],"prefix":"10.1111","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-4224","authenticated-orcid":false,"given":"Marshall C.","family":"Strother","sequence":"first","affiliation":[{"name":"Division of Urology Department of Surgery Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kutikov","sequence":"additional","affiliation":[{"name":"Division of Urology Department of Surgery Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Epstein","sequence":"additional","affiliation":[{"name":"Department of Urology Lewis Katz School of Medicine at Temple University Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Bochner","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College Thomas Jefferson University Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengying","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Handorf","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Ghatalia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Division of Urology Department of Surgery Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Urology Department of Surgery Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalia","family":"Viterbo","sequence":"additional","affiliation":[{"name":"Division of Urology Department of Surgery Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fern","family":"Anari","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc C.","family":"Smaldone","sequence":"additional","affiliation":[{"name":"Division of Urology Department of Surgery Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Zibelman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Uzzo","sequence":"additional","affiliation":[{"name":"Division of Urology Department of Surgery Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Geynisman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.04.086"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.12.062"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02292-8"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2007.0114"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-001-0004-z"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.06.020"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2010.02.205"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160211"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70275-8"},{"key":"e_1_2_6_12_1","unstructured":"Common Terminology Criteria for Adverse Events v3.0 2006. Available at:https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed September 2020"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2465"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.07.009"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.07.072"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72820-y"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.03.091"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12274"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2008.06.001"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.07.009"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00158"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.20.4005"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(89)90125-2"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-017-0392-z"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2244"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS537"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15410","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.15410","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:24:57Z","timestamp":1761733497000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.15410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/bju.15410"],"URL":"https:\/\/doi.org\/10.1111\/bju.15410","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"2021-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}